Answers are grounded in this paper and cite their sources.
Comparative in vitro study reveals altered IGF binding protein expression in knee mesenchymal stem cells from diabetic donors, highlighting targets to improve bone regeneration.
Diabetes mellitus (T2DM) represents a major health problem with several potentially life-threatening complications including cardiovascular disease and osteopathy. Bone marrow mesenchymal stem cells (BM-MSCs) are a promising candidate for bone regeneration, and the insulin-like growth factor (IGF) axis plays a fundamental role in both bone regeneration and stem cell biology. Still, its expression profile is yet to be assessed in diabetic BM-MSCs. This study investigated IGF axis gene and protein expression in BM-MSCs isolated from the knee joints of diabetic and non-diabetic donors. BM-MSCs were cultured under basal and osteogenic conditions for 1, 2 and 3 weeks. Relative expression levels of the IGF axis genes were assessed using qPCR while protein concentrations of IGFBP-2, -3 and -4 were assessed using ELISA. Diabetic BM-MSCs showed lower mRNA levels of IGF binding proteins (IGFBP)-2, -3 and -4 but both cell populations displayed comparable protein levels. Moreover, the osteogenic cultures of diabetic and non-diabetic BM-MSCs equally demonstrated a trend of IGFBP-2 upregulation along with IGF-1 and IGFBP-5 downregulation. Non-diabetic BM-MSCs showed significant time-dependent increases in IGFBP-3 and -4 concentrations in basal and osteogenic cultures respectively. These molecules could be addressed to improve the regenerative potentials of BM-MSCs particularly under diabetic conditions, and further research is warranted into the possible roles of IGFBPs proteinases and their inhibitors in bone biology.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: